arXiv · 2411.03361
Age Normalized Testosterone Peaks at Series B for Male Startup Founders
Abstract
In a study of 107 male Y Combinator founders, a surprising correlation between age-normalized testosterone and company stage was uncovered. Testosterone, a hormone associated with confidence, dominance, and drive, increased by 55.7% from pre-seed to seed funding, peaking at the Series B stage, where levels were 99.6% higher than pre-seed. After series B funding, testosterone was observed to drop by 42.2%, coinciding with a spike in cortisol levels. This age-normalized biomarker analysis supports the dual-hormone hypothesis, illustrating that early startup success fosters feelings of dominance and confidence, while later-stage pressures and stresses erode these feelings. An alternative interpretation of the data, which suggests the opportunity for a longitudinal study, is that male founders with higher testosterone are more likely to raise larger rounds of funding.
Explore related subjects
Keep this discovery
Jordan Moradian, Michael Dubrovsky, Megha Sama, Pavel Korecky, Sidarth Kulkarni, Yaniv Goder, Diedrik Vermeulen. 2024-11-05. Age Normalized Testosterone Peaks at Series B for Male Startup Founders. https://arxiv.org/abs/2411.03361
Cite the original work for its findings. Save a collection to share your selection of sources.